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Abstract
Context: Fetal growth involves highly complex molecular pathways. IGF2 is a key paternally expressed growth hormone
that is critical for in utero growth in mice. Its role in human fetal growth has remained ambiguous, as it has only been
studied in term tissues. Conversely the maternally expressed growth suppressor, PHLDA2, has a significant negative
correlation between its term placental expression and birth weight.
Objective: The aim of this study is to address the role in early gestation of expression of IGF1, IGF2, their receptors IGF1R and
IGF2R, and PHLDA2 on term birth weight.
Design: Real-time quantitative PCR was used to investigate mRNA expression of IGF1, IGF2, IGF1R, IGF2R and PHLDA2 in
chorionic villus samples (CVS) (n = 260) collected at 11–13 weeks’ gestation. Expression was correlated with term birth
weight using statistical package R including correction for several confounding factors.
Results: Transcript levels of IGF2 and IGF2R revealed a significant positive correlation with birth weight (0.009 and 0.04,
respectively). No effect was observed for IGF1, IGF1R or PHLDA2 and birth weight. Critically, small for gestational age (SGA)
neonates had significantly lower IGF2 levels than appropriate for gestational age neonates (p = 3?661027).
Interpretation: Our findings show that IGF2 mRNA levels at 12 weeks gestation could provide a useful predictor of future
fetal growth to term, potentially predicting SGA babies. SGA babies are known to be at a higher risk for type 2 diabetes. This
research reveals an imprinted, parentally driven rheostat for in utero growth.
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Introduction
Fetal growth involves a complex interaction between genes and
the environment, with such significant complexity that many of the
molecular pathways remain to be elucidated. Normal fetal growth
depends on the successful nutrient exchange between the mother
and the fetus via the placenta. When this critical balance is
impaired it can result in a small for gestational age (SGA) baby [1].
SGA neonates have a reported incidence of ,6% of pregnancies
in developed countries and as high as 40% in some developing
countries [2,3]. SGA is also associated with an increased risk of
neonatal death. Although the survivors do exhibit catch up
growth, it is important to note that they remain at a higher risk for
common, late onset chronic diseases such as type 2 diabetes (T2D)
and cardiovascular disease [4]. Hales et al., (1991) reported a
graded inverse association between birth weight and T2D risk with
the highest risks of T2D occurring at the lowest levels of birth
weight [5]. In a more recent meta-analysis, an increased risk for
T2D (OR=1.47) is seen for SGA versus appropriate for
gestational age (AGA) neonates [6].
One group of growth genes of particular interest are the
imprinted genes that are found almost exclusively in Eutherian
(placental) mammals. Genomic imprinting defines allele-specific,
differential expression of a gene, according to its parent of origin.
If the paternal allele is expressed, the maternal allele is imprinted
(silenced) and vice versa. The ‘‘parental conflict hypothesis’’ is still
the most widely accepted explanation for the evolution of genomic
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imprinting [7]. It has been suggested that expression of the father’s
genes enhance fetal growth improving the success of the paternal
genome to be passed on. In contrast, the mother’s genome limits
fetal growth, distributing equal resources to each of her offspring,
whilst ensuring her own survival post birth allowing her to
reproduce again. Studies of imprinted genes generally support this
model, with one of the most striking examples being the reciprocal
imprinting effects and associated growth patterns for mouse
insulin-like growth factor 2 (Igf2) and its chelating receptor Igf2r
[8]. In transgenic mice, loss of function of the paternally-expressed
Igf2 results in a 40% reduction in birth weight which contrasts with
loss of the maternally-expressed Igf2r, resulting in a 30% increase
in birth weight [9,10]. In addition, IGF2 has been implicated in
two imprinted human growth disorders, the overgrowth, Beck-
with-Wiedemann syndrome (BWS) [11] and the growth restricting
Silver-Russell syndrome (SRS) [12].
Pleckstrin homology-like domain family A member 2 (PHLDA2)
is maternally expressed, paternally imprinted, in both humans and
mice [13]. Involvement of Phlda2 in growth and development of
the placenta was demonstrated by knockout mouse models that
were associated with a significant increase in placental size during
mid to late gestation [14]. Studies that have investigated the
human placental expression of PHLDA2 report increased expres-
sion in SGA pregnancies and a negative association with birth
weight [15,16,17].
Insulin-like growth factor 1 (IGF1) and its primary binding
receptor IGF1R are not imprinted. IGF1 exerts its growth
properties on almost every cell in the body. A homozygous partial
deletion of Igf1r in mice stunted height and weight, as well as
disrupted the pubertal growth spurt. A complete inactivation of
Igf1r is lethal in the neonatal period [18]. In contrast to Igf2
deficient mice, restriction of growth was seen to continue into the
postnatal period in the Igf1 mutants [19].
The analyses of human placental expression of IGF1, IGF2,
IG1R and IGF2R have previously been confined to samples
obtained at the time of birth. IGF1 under-expression was observed
in term placental samples from SGA pregnancies [20], while
mutations in the IGF1R gene led to abnormalities in the function
of IGF1 receptors that may also slow down intrauterine and
subsequent growth in humans [21].
Studies on IGF2 have reported conflicting results. Some
demonstrate no correlation between IGF2 expression and birth
weight [16] whereas others have variably shown that in SGA
pregnancies compared to controls, IGF2 expression is either
increased [22], decreased [15,23,24], or similar [25], including at
the protein level [26]. Moreover, studies have either shown no
significant relationship between IGF2 cord serum levels and size at
birth [27], or a positive effect on birth weight [28]. In others, IGF2
cord blood levels were significantly correlated with birth weight
only when its interaction with IGF2R was taken into account [29].
The profound role of the IGF1 and IGF2 pathways in the
regulation of fetal growth have been established largely based on
experiments using the mouse as a model [9,10,18]. Analysis in
humans has been hampered by the lack of available tissue to study
during the course of pregnancy and has therefore relied on the use
of term placenta, at a time when this tissue has become redundant
and therefore the levels of gene expression may no longer reliably
reflect the needs of the growing baby. To fully assess the role of
these growth factors and their receptors, we have focused on an
earlier developmental time point when these genes are much more
likely to measure functionally relevant expression levels.
Methods
Study population
Chorionic villus sampling (CVS) was performed at 11–13 weeks
of gestation in 260 singleton pregnancies that subsequently
resulted in normal live births at term. The samples were collected
from women undergoing CVS for prenatal diagnosis of chromo-
somal defects at King’s College Hospital London. The excess
tissue samples used for this study were obtained from women
agreeing to participate in research, which was approved by the
King’s College Hospital Ethics Committee.
Demographic characteristics were recorded including maternal
age, racial origin, smoking status, parity and body mass index as
well as pregnancy outcomes such as gestational age at delivery, sex
and birth weight. Other birth parameters such as placental weight
were not available, nor were blood or tissue samples from the
newborn baby. The pregnancies were subdivided according to the
birth weight of neonates into small for gestational age (SGA) with
birth weight ,10th percentile, large (LGA) with birth weight
.90th percentile and appropriate (AGA).
Preparation of DNA and RNA from chorionic villus
samples
DNA and RNA were extracted using the iPrep Purification
Instrument (Invitrogen), either by use of the iPrepTM ChargeS-
witchH gDNA Tissue Kit, or iPrepTM PureLinkTM Total RNA
and TrizolH Plus RNA kit including DNAse treatment, according
to the manufacturer’s instructions.
Reverse transcription
Reverse transcriptase (RT) methodology was based on a
standard protocol using M-MLV reverse transcriptase and
random primer hexamers (Promega). Primers for the housekeep-
ing gene b-actin (ACTB) were used to check the integrity of the
cDNA and ensure no DNA contamination. The forward (F) and
reverse (R) primers spanned an intron and the sequences are: b-
actin.F- gtcttcccctccatcgtg and b-actin.R- ggtcatcttctcgcggttg.
Polymerase Chain Reaction (PCR)
Genomic DNA and cDNA from CVS were amplified by PCR
before sequencing. Primers (59 to 39 sequence) used for genomic
DNA are IGF2.F- aacaccccacaaaagctcag; IGF2.R- tgcatg-
gattttggttttca; IGF2R.F- gaaacacaaaacctacgacc; IGF2R.R-
agaacccaaaagagccaacc; PHLDA2.F- caaaccccgcacgccatgag and
PHLDA2.R- ctgtgcccattgcaaataaatc. The same primers were used
for cDNA with the exception of IGF2R.R- cctttggagtacgtgacaac.
20 ul reactions were set up and thermal cycling conditions were
94uC for 5 min, 94uC for 30 sec, 60uC for 30 sec, 72uC for 30 sec
for 35 cycles, and 72uC for 2 min.
Imprinting analysis
Imprinting analysis of IGF2, IGF2R and PHLDA2 in CVS was
carried out by DNA sequence analysis of expressed single
nucleotide polymorphisms (SNP) in CVS gDNA after amplifica-
tion using specific primers (IGF2.F- aacaccccacaaaagctcag;
IGF2R.R- cctttggagtacgtgacaac and PHLDA2.F- caaaccccgcacgc-
catgag). Corresponding cDNA samples were screened in patients
heterozygous for the IGF2 A/G (rs680), IGF2R A/G (rs1805075)
and PHLDA2 A/G (rs1056819) SNPs (http://www.ncbi.nlm.nih.
gov/projects /SNP/). Sequencing reactions were prepared
according to the manufacturer’s instructions (Applied Biosystems)
using the ABI Prism Big Dye terminator cycle sequencing ready
reaction kit (BDT v1.1). Sequencing products were run on an ABI
IGF2 Expression Correlates with Birth Weight
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Prism 3730 DNA analyzer, and the read-out was analysed with
SequencherTM v4.8 (Gene Codes Corporation).
Real-time quantitative PCR
The quantitative expression analysis of the genes of interest,
IGF1, IGF2, IGF1R, IGF2R and PHLDA2 as well as the
endogenous control gene L19 (a housekeeping gene ubiquitously
expressed in the placenta) [16] was determined by real-time
quantitative PCR (RTqPCR) with SYBR Green (ABI) using the
StepOnePlus Real-Time PCR System (ABI). Primers (59 to 39
sequence) used for quantitative analysis are IGF1.F- ggaggctgga-
gatgtattgc; IGF1.R- acttgcttctgtcccctcct; IGF2.F- cgagagggacgtgtc-
gacc; IGF2.R- ggactgcttccaggtgtcata; IGF2R.F- ccggcgtgctctgga;
IGF2R.R- ccagagggtcacagtggaaga; IGF1R.F- ccaagggtgtggtgaaa-
gat; IGF1R.R- tccatgatgaccagtgttgg; PHLDA2.F- ccatccccgcagcc-
caaacc; PHLDA2.R- ccacgtcctagcctgggtcc; L19.F- gcggaagggta-
cagccaat and L19.R- caggctgtgatacatgtggcg. All primer sets were
free of primer-dimer products. The RTqPCR assays were run in
triplicate for each sample, with the gene of interest and
housekeeping gene run on the same 96-well plates. A control
pool of CVS cDNA was also included on each plate. Amplification
conditions include initial incubation at 95uC for 10 min and
repetitive denaturation at 95uC for 15 sec and annealing at 60uC
for 1 min for 40 cycles.
After amplification, quantitative expression levels were obtained
using the StepOne software (version 2.1). All triplicate cycle
threshold (CT) values were within 1 CT of each other. The
quantitative values for each triplicate were averaged and the
Figure 1. mRNA expression levels of IGF2, IGF2R, PHLDA2, IGF1 and IGF1R in chorionic villi. The expression levels of IGF2, IGF2R, PHLDA2,
IGF1 and IGF1R after standardization to the endogenous control gene L19, in relation to birth weight corrected for parity, sex, GA at term, maternal
BMI and smoking status. Significant associations were observed for CVS expression of A) IGF2 (p = 0.009) and B) IGF2R (p = 0.04). No significant
association was found for C) PHLDA2 (p = 0.73), for D) IGF1 (p = 0.48) or for E) IGF1R (p = 0.08).
doi:10.1371/journal.pone.0085454.g001
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relative expression of the genes of interest was determined by a
ratio of their expression to that of the L19 housekeeping gene for
the same sample.
Statistical analysis
Standard multiple linear regression models were used to
examine the correlation of IGF1, IGF2, IGF2R, IGF1R and
PHLDA2 relative expression values to birth weight after adjust-
ment for gestational age at delivery, sex, parity, maternal age,
smoking status and maternal body mass index. Any outliers more
than 2 standard deviations from the mean were removed. The
analysis of variance (one-way ANOVA) was used to compare the
gene expression means between the three different categorical
birth weight groups (SGA, AGA, LGA) taking into consideration
any confounding factors. Statistical package ‘‘R’’ (version 2.13.0)
was used for the analyses and for calculating adjusted R-squared
(R2) values. Significance was defined as p,0.05.
Results
In this study, we have investigated the relationship between
IGF1, IGF2, IGF2R, IGF1R and PHLDA2 mRNA levels in first-
trimester placental tissue with the birth weight of the resultant
term new born babies. We correlate this data taking into account
the carefully recorded birth parameters that may have a
confounding effect (gestational age, sex, parity, maternal BMI
and smoking status; figure S1). Regression analysis was performed
after standardization to the endogenous control gene L19, in
relation to birth weight corrected for confounding factors.
Significant associations were observed for expression of IGF2
(p = 0.009) and IGF2R (p = 0.04) between CVS tissue and birth
weight (figure 1A–B). Importantly the range of IGF2 in relative
expression units was from 1.5–12 with one relative expression unit
being equivalent to a change in birth weight of 63 g. No
association was found for PHLDA2 (p = 0.73), IGF1 (p = 0.48) or
IGF1R (p = 0.08) between CVS tissue and birth weight (figure 1C–
E).
As both IGF1 and IGF2 bind to the IGF1R and only IGF2
binds to the IGF2R we decided to look at this relationship between
the ligands and their receptors and any correlation they might
have with birth weight. The ratio of IGF2 to IGF1R (p = 0.005) was
significantly associated with birth weight but no association was
found for the ratio of IGF1 to IGF1R (p = 0.76) or the ratio of IGF2
to IGF2R (p = 0.93) between CVS tissue and birth weight (figure 2).
To investigate the whole growth spectrum we subdivided the
pregnancies into small for gestational age (SGA; n= 50) with birth
weight ,10th percentile, large (LGA; n= 65) with birth weight
.90th percentile and appropriate (AGA; n= 145). In the SGA
group compared to the AGA group, IGF2 expression was reduced
by statistically significant amounts (p = 3.661027), despite no
significant differences in the expression levels of individual
receptors (IGF2R, p = 0.76 or IGF1R, p = 0.15). In the LGA group
IGF2R expression was found to be higher than in the AGA group
(p = 0.02) and IGF1R expression was lower than in the SGA group
(p = 0.05) (figure 3).
Given that IGF2 and PHLDA2 are both known to be imprinted
in mouse and human [8,13,30], we wanted to confirm that
monoallelic expression was maintained in CVS material, since
reversion to biallelic expression may impact on mRNA levels.
Furthermore, IGF2R in the human population is reported to be
monoallelically expressed (i.e. imprinted) in only 10% of individ-
uals, which is in contrast to the mouse, where it is fully imprinted
[31]. We therefore wished to confirm its imprinting status in CVS
material and to investigate for any potential skewing. The
transcribed SNPs rs680 (IGF2), rs1805075 (IGF2R) and
rs1056819 (PHLDA2) were used to report on allele-specific
expression and thus determine imprinting status of IGF2, IGF2R
and PHLDA2. Genomic DNA extracted from the CVS from 200
patients were tested for heterozygosity at these SNPs, with 40
samples found to be informative at rs680 for IGF2, 24 samples at
rs1805075 for IGF2R and 21 samples at rs1056819 for PHLDA2.
The 40 informative IGF2 individuals and the 21 informative
PHLDA2 individuals were all found to be monoallelically
expressed. For the 24 samples informative for IGF2R, 21 (88%)
Figure 2. mRNA expression levels of IGF1/IGF1R, IGF2/IGF2R and IGF2/IGF1R in chorionic villi. The expression levels of IGF1/IGF1R, IGF2/
IGF2R and IGF2/IGF1R after standardization to the endogenous control gene L19, in relation to birth weight corrected for parity, sex, GA at term,
maternal BMI and smoking status. No significant association was found for A) the ratio of IGF1 to IGF1R (p = 0.76), or for B) the ratio of IGF2 to IGF2R
(p = 0.93). Significant association was observed for CVS expression of C) the ratio of IGF2 to IGF1R (p = 0.005) and birth weight.
doi:10.1371/journal.pone.0085454.g002
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were biallellically expressed for IGF2R and 3 (12%) were
monoallelic, which is similar to the expected population frequency
(figure 4). Thus, skewed monoallelic/biallelic expression was
unlikely to be a factor reflected in the relative expression levels
associated with birth weight.
Discussion
Previous studies have linked IGF2 expression to birth weight, by
showing that IGF2 in term placenta is decreased in SGA
pregnancies compared to controls [23,24]. However, the first
trimester IGF2 expression data reported in this study, provides the
first evidence for the role of this paternally expressed imprinted
gene as an in utero fetal growth enhancer this early in human
pregnancy. This is compatible with results previously described in
animal studies [9,32]. For example, in mouse experiments,
paternally expressed Igf2 was reported to control 40% of fetal
growth, with the maternally expressed gene Igf2r limiting fetal
growth [10,33]. In humans, IGF2 is consistently maternally
imprinted and therefore a paternal-expression driven growth
promoter. However, in humans, IGF2R is polymorphic for its
imprinting status with 90% of individuals showing biallelic
expression [31]. This indicates a possible shift in the mechanism
of its regulation of expression away from that used in the mouse.
Interestingly, here, the samples showing monallelic expression of
IGF2R had similar levels to those showing biallelic expression.
As fetal size is subject to both positive and negative regulation,
IGF2 and IGF2R genes can exert opposite forces on the fetus,
achieving a fine degree of control over the growth process. As
levels of IGF2 increase in the fetus, the levels of IGF2R can also
increase, resulting in clearance of IGF2 from plasma and tissue
fluids, correcting and maintaining levels of IGF2 in the circulation.
This acts as a fine-tuning rheostat designed to prevent babies from
overgrowth in order to maintain a normal growth trajectory. This
is also supported by the fact that no association was observed
between the IGF2/IGF2R expression levels and birth weight, as the
ligand and the receptor work tightly together to regulate growth.
The same applies for IGF1 and its regulating receptor IGF1R.
In this study, expression of IGF1 in chorionic villi was not
associated with birth weight outcome. These results directly
Figure 3. mRNA expression levels of IGF2, IGF2R, and IGF1R in chorionic villi according to BW centile. Relative IGF2, IGF2R, and IGF1R
expression levels in the pregnancies with small (SGA), appropriate (AGA) and large (LGA) neonates. In the SGA group, compared to the AGA group, A)
IGF2 expression was lower (p = 3?661027), but there was no significant difference in the expression levels of B) IGF2R (p = 0?76) or C) IGF1R (p = 0?15).
In the LGA group B) IGF2R expression was higher than in the AGA group (p = 0?02) and C) IGF1R expression was lower than in the SGA group
(p = 0?05).
doi:10.1371/journal.pone.0085454.g003
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contradict findings from studies involving mouse models which
highlighted IGF1 role in the regulation of both pre- and postnatal
growth [34]. There also remains a strong possibility that IGF1 is
indeed relevant to intrauterine growth in the later stages of
pregnancy as it is preparing the baby for a postnatal life. While
fetal chorionic fetal samples in the present cohort proved an
opportunity to assess correlation between gene expression and fetal
growth in early gestation (11–13 weeks), this narrow window might
not be the best to investigate IGF1 expression, as IGF1 does not
appear in the fetal circulation until later [35].
Although previous studies have shown that placental PHLDA2
expression is negatively associated with birth weight [16,17], in our
study no statistically significant association was observed between
PHLDA2 expression levels in CVS and birth weight. This suggests
that maternally expressed PHLDA2 is suppressing the baby’s
growth later in pregnancy rather than early on. Previous studies
investigating term placental IGF2 expression have shown incon-
clusive results. However, in our study a statistically significant
association was observed between IGF2 expression levels in CVS
and birth weight, suggesting that the paternal genome is
promoting the baby’s growth earlier in pregnancy. Therefore,
the two parental genomes appear to be acting at different times
during pregnancy to control the fetal weight. This supports the
idea that whilst increased fetal growth is important early on, it
must still require careful regulation by the mother to ensure a
successful birth.
In our study, SGA neonates had significantly lower IGF2
expression levels compared to AGA neonates, but no differences
were observed between the levels of the receptors IGF2R and
IGF1R. This highlights the importance of the IGF2 ligand rather
than the receptor level in determining size of the neonate in SGA
pregnancies. This is in agreement with previous studies investi-
gating IGF2 mRNA levels in the placentas from growth-restricted
pregnancies [23,24].
Figure 4. Imprinting analysis of IGF2, PHLDA2 and IGF2R. Representative sequencing chromatograms are shown from one of the 40 informative
CVS samples for the IGF2 A/G polymorphism (rs680) (A, B), one (from 21) for the PHLDA2 A/G polymorphism (rs1056819) (C, D) and two (from 24) for
the IGF2R A/G polymorphism (rs1805075) (E, F, G, H). Heterozygous genomic CVS DNA sequence is shown in A), C), E) and G). While monoallelic
expression from the corresponding cDNA samples are shown in B), D) and H). Monoallelic expression in cDNA was found in all informative IGF2 and
PHLDA2 samples as well as 12% of IGF2R samples. Biallelic expression, as shown in F), was found in the majority (88%) of informative cDNA samples
for IGF2R.
doi:10.1371/journal.pone.0085454.g004
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To better understand the causes and consequences of fetal
growth restriction as a human pregnancy complication, we focused
on available tissue from the first trimester, as this time window is
more likely to accurately reflect the in utero growth potential. We
used a larger sample size and we investigated the whole growth
spectrum including not only SGA but also LGA neonates. We
reasoned that extending the investigation of these genes to samples
displaying macrosomic birth weight would also reveal further
correlations between growth parameters and gene expression. In
this study, LGA neonates had higher IGF2R expression levels
compared to AGA neonates and lower IGF1R levels compared to
SGA babies. Similar results have been reported in placenta tissue
for IGF1R mRNA levels alone [36], and this suggests that fetuses
with high birth weight are producing more IGF2R and
correspondingly less IGF1R, which could remove IGF2. This
balance may represent another important compensatory mecha-
nism in response to fetal overgrowth. This is also supported by the
fact that a significant association was observed between the ratio of
IGF2 to IGF1R and birth weight, suggesting that the levels of
IGF1R in LGA neonates decrease as their IGF2 levels increase, to
avoid any further increase in size.
The ‘‘small baby syndrome hypothesis’’ proposed by Barker et
al., (1993) suggests that there is an inverse linear relation between
birth weight and T2D [37]. This is also supported by a large meta-
analysis [38]. The mechanisms by which birth weight is related to
T2D is still under debate, Barker et al. claim that this relationship
reflects long-term consequences of under-nutrition in utero [37],
whereas others do not see under-nutrition as playing a significant
role [39]. Interestingly, specific fetal IGF2 paternal haplotypes are
linked to higher maternal glucose levels that increase the risk of
gestational diabetes [40]. Nevertheless the amount of IGF2
available from the placenta early in the first trimester is likely to
be a major factor in promoting growth.
An important aim for antenatal care is the prediction, detection
and treatment of anomalous fetal growth. We know that variation
in size at birth results from interaction between fetal genetic factors
and the maternal genetic and uterine environment. In this study
we also implicate the important role of the father’s genes in fetal
growth in utero. Understanding the developmental role, function
and parent-of-origin effect of critical imprinted genes during
human fetal growth will make an important contribution to
effective clinical evaluation of growth disorders and their
association with longer term, metabolically related, health risks
such as T2D. Determination of paternal IGF2 expression in the
first trimester, potentially in maternal blood, may act as a
predictor of fetal growth trajectory for later in the pregnancy.
An early growth biomarker could be invaluable to alert
Obstetricians and Neonatologists towards closer ‘at risk’ pregnan-
cy surveillance.
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Figure S1 Confounding factors. Correlation of birth weight
with gestational age at term (p= 4.8610215; Fig. S1A), with
maternal BMI (p = 0.0012; Fig. S1B), with gender (p = 1.461027;
Fig. S1C), with parity (p = 7.561025; Fig. S1D), and maternal
smoking status (p = 0.33; Fig S1E).
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